China Pharma Holdings Inc (OTC: CPHI) is a China-based pharmaceutical and healthcare products company that manufactures and sells drugs and health-related consumer products through its operating subsidiary Hainan Helpson Medical & Biotechnology Co., Ltd. Revenue comes from transactional product sales, with the company also pursuing OEM manufacturing arrangements to increase equipment utilization. CPHI operates in China's pharmaceutical market, which is shaped by national centralized drug procurement programs and the medical insurance fund, which covered approximately 40% of healthcare costs as of the period referenced in the FY2025 10-K filing dated April 1, 2026. The company has disclosed going concern doubt, with management planning to expand advance-payment sales, accelerate accounts receivable collection, pursue government subsidies, and launch new nutrition and health products, including freeze-dried bird's nest and Buddha's hand rose items that had obtained food production licenses as of the filing date. Zhilin Li serves as Chairperson, President, CEO, and interim CFO, as of April 1, 2026.

Revenue model

Transactional sales of pharmaceutical and health products; OEM manufacturing for third parties to increase equipment utilization; advance-payment sales model being expanded to improve cash flow (per 10-K filed April 1, 2026).

Products and services

Prescription and over-the-counter drugs manufactured under GMP-compliant production lines; Noni enzyme antioxidant food supplement (launched end of 2018); wash-free sanitizers and masks (launched 2020); freeze-dried bird's nest and Buddha's hand rose nutrition products (food production licenses obtained, planned launch as of April 1, 2026 filing); comprehensive healthcare products under development (per 10-K filed April 1, 2026).

Customers and end markets

Hospitals, physicians, and hospital pharmacists and procurement departments in China; retail consumers for health supplement and consumer health products; end markets include China's pharmaceutical drug market subject to national centralized procurement, and the broader comprehensive healthcare market projected by the Chinese government to reach RMB 16 trillion (approximately $2.5 trillion) by 2030 (per Healthy China 2030 Outline cited in 10-K filed April 1, 2026).

Value-chain role

Pharmaceutical manufacturer and health product seller; also pursues technology transfer agreements and OEM production for third parties; operating subsidiary Hainan Helpson Medical & Biotechnology Co., Ltd. holds production licenses and regulatory approvals (per 10-K filed April 1, 2026).

Geographic exposure

Operations based in China (Hainan province); incorporated and publicly listed in the United States; subject to PRC regulatory oversight including MOFCOM, SAFE, NDRC, and CSRC for capital flows and securities filings (per 10-K filed April 1, 2026).

Source: SEC 10-K, filed 2026-04-01

Industry: Pharmaceutical Preparations Peers: China SXT Pharmaceuticals Inc SUNWIN STEVIA INTERNATIONAL, INC. BGM Group Ltd Universe Pharmaceuticals Inc